Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Pancreatic Ductal Adenocarcinoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

Pancreatic Cancer (499)

Pancreatic Adenocarcinoma (81)

Pancreatic Cancer (499)

Pancreatic Adenocarcinoma (81)

›

NRG1 fusion	Pancreatic Ductal Adenocarcinoma	NRG1 fusion	Pancreatic Ductal Adenocarcinoma	zenocutuzumab-zbco Sensitive: A1 - Approval zenocutuzumab-zbco Sensitive : A1	zenocutuzumab-zbco Sensitive: A1 - Approval zenocutuzumab-zbco Sensitive : A1
No biomarker	Pancreatic Ductal Adenocarcinoma	No biomarker	Pancreatic Ductal Adenocarcinoma	SBP-101 Sensitive: B - Late Trials SBP-101 Sensitive : B	SBP-101 Sensitive: B - Late Trials SBP-101 Sensitive : B
No biomarker	Pancreatic Ductal Adenocarcinoma	No biomarker	Pancreatic Ductal Adenocarcinoma	gemcitabine Sensitive: B - Late Trials gemcitabine Sensitive : B	gemcitabine Sensitive: B - Late Trials gemcitabine Sensitive : B
No biomarker	Pancreatic Ductal Adenocarcinoma	No biomarker	Pancreatic Ductal Adenocarcinoma	gemcitabine + capecitabine Sensitive: B - Late Trials gemcitabine + capecitabine Sensitive : B	gemcitabine + capecitabine Sensitive: B - Late Trials gemcitabine + capecitabine Sensitive : B
CCL11 overexpression	Pancreatic Ductal Adenocarcinoma	CCL11 overexpression	Pancreatic Ductal Adenocarcinoma	tertomotide Sensitive: B - Late Trials tertomotide Sensitive : B	tertomotide Sensitive: B - Late Trials tertomotide Sensitive : B
No biomarker	Pancreatic Ductal Adenocarcinoma	No biomarker	Pancreatic Ductal Adenocarcinoma	LSTA1 Sensitive: B - Late Trials LSTA1 Sensitive : B	LSTA1 Sensitive: B - Late Trials LSTA1 Sensitive : B
KRAS wild-type	Pancreatic Ductal Adenocarcinoma	KRAS wild-type	Pancreatic Ductal Adenocarcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: B - Late Trials gemcitabine + albumin-bound paclitaxel Sensitive : B	gemcitabine + albumin-bound paclitaxel Sensitive: B - Late Trials gemcitabine + albumin-bound paclitaxel Sensitive : B
KRAS wild-type	Pancreatic Ductal Adenocarcinoma	KRAS wild-type	Pancreatic Ductal Adenocarcinoma	5-fluorouracil + oxaliplatin Sensitive: B - Late Trials 5-fluorouracil + oxaliplatin Sensitive : B	5-fluorouracil + oxaliplatin Sensitive: B - Late Trials 5-fluorouracil + oxaliplatin Sensitive : B
No biomarker	Pancreatic Ductal Adenocarcinoma	No biomarker	Pancreatic Ductal Adenocarcinoma	atezolizumab + pelareorep Sensitive: B - Late Trials atezolizumab + pelareorep Sensitive : B	atezolizumab + pelareorep Sensitive: B - Late Trials atezolizumab + pelareorep Sensitive : B
No biomarker	Pancreatic Ductal Adenocarcinoma	No biomarker	Pancreatic Ductal Adenocarcinoma	aglatimagene besadenovec Sensitive: B - Late Trials aglatimagene besadenovec Sensitive : B	aglatimagene besadenovec Sensitive: B - Late Trials aglatimagene besadenovec Sensitive : B
BRCA2 mutation	Pancreatic Ductal Adenocarcinoma	BRCA2 mutation	Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
ATM mutation	Pancreatic Ductal Adenocarcinoma	ATM mutation	Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1